Viking Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Viking Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- VKTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001607678
Board of directors
-
Brian Lian · Director · President & CEOSince 2023
-
Charles A. Rowland Jr. · DirectorSince 2023
-
Dorothy Elizabeth Kelly-Gemmell · DirectorSince 2026
-
J. Matthew Singleton · DirectorSince 2023
-
Lawson Macartney · DirectorSince 2023
-
Matthew W. Foehr · DirectorSince 2023
-
Sarah Kathryn Rouan · DirectorSince 2023
Chief executives
Brian Lian
· President & CEO
Dates unknown
Board connections
1 of this board's directors also sit on 1 other board.
- via Matthew W. Foehr
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $149,913
- 1 purchase by 1 insider
- Sold, last 12 months
- $22,252,290
- 20 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 1, 2026 | Dorothy Elizabeth Kelly-Gemmell Director | Grant or award | +6,333 | — | — |
| Jul 29, 2026 | Brian Lian Director, Officer (President & CEO) | Open-market sale | −148,517 | $33.32 | $4,947,888 |
| Jul 29, 2026 | Mancini Marianna Officer (Chief Operating Officer) | Open-market sale | −18,217 | $33.47 | $609,636 |
| Jul 29, 2026 | ZANTE GREG Officer (Chief Financial Officer) | Open-market sale | −21,217 | $33.47 | $710,141 |
| Jul 28, 2026 | Brian Lian Director, Officer (President & CEO) | Grant or award | +221,667 | — | — |
| Jul 28, 2026 | Mancini Marianna Officer (Chief Operating Officer) | Grant or award | +31,667 | — | — |
| Jul 28, 2026 | ZANTE GREG Officer (Chief Financial Officer) | Grant or award | +31,667 | — | — |
| Mar 10, 2026 | Aubuchon Neil William Officer (Chief Commercial Officer) | Open-market purchase | +4,475 | $33.50 | $149,913 |
| Jan 5, 2026 | ZANTE GREG Officer (Chief Financial Officer) | Open-market sale | −31,961 | $32.30 | $1,032,340 |
| Jan 5, 2026 | Mancini Marianna Officer (Chief Operating Officer) | Open-market sale | −31,961 | $32.29 | $1,032,021 |
| Jan 5, 2026 | Brian Lian Director, Officer (President & CEO) | Open-market sale | −132,454 | $32.29 | $4,276,940 |
| Jan 5, 2026 | ZANTE GREG Officer (Chief Financial Officer) | Open-market sale | −13,900 | $33.38 | $463,982 |
| Jan 5, 2026 | Mancini Marianna Officer (Chief Operating Officer) | Open-market sale | −13,600 | $33.37 | $453,832 |
| Jan 5, 2026 | Brian Lian Director, Officer (President & CEO) | Open-market sale | −53,279 | $33.38 | $1,778,453 |
| Jan 5, 2026 | ZANTE GREG Officer (Chief Financial Officer) | Open-market sale | −10,300 | $34.24 | $352,672 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.